Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

New Balance Launches Exclusive Cycle For Survival WX09 NBCycle Shoe To Support Rare Cancer Research

Cycle for Survival
Posted on: 01 Dec 17
New Balance Launches Exclusive Cycle For Survival WX09 NBCycle Shoe To Support Rare Cancer Research New Balance will donate 10 percent of the shoe's suggested retail price to support rare cancer research led by Memorial Sloan Kettering Cancer Center

PR Newswire

NEW YORK, Dec. 1, 2017

NEW YORK, Dec. 1, 2017 /PRNewswire/ -- Starting today, New Balance will introduce the Cycle for Survival WX09 NBCycle shoe as part of its line of premier athletic gear. The exclusive indoor cycling shoe benefits rare cancer research and features orange design accents as a tribute to the Cycle for Survival community of patients, survivors, doctors, caregivers and supporters fighting back against rare cancers.

Beginning December 1, 2017, New Balance will donate 10 percent of the suggested retail price for each Cycle for Survival WX09 NBCycle shoe exclusively sold on to Memorial Sloan Kettering Cancer Center (MSK). Cycle for Survival, owned and operated by MSK, is the movement to beat rare cancers. 100 percent of every dollar donated to Cycle for Survival goes directly to groundbreaking rare cancer research.

At a suggested retail price of $124.99, the Cycle for Survival WX09 NBCycle is made of a breathable mesh upper and NBFresh lining, to help resist odor. The adjustable mid-foot strap allows for maximum comfort, while the full-length midsole supports power transfer during cycling. The shoe is extremely versatile: a unique design that is walkable to and from the cycling studio. The Cycle for Survival WX09 NBCycle is available in women's sizes 5 through 12 and is compatible with SPD® cycling cleats. Hi-res images and product specifications for the Cycle for Survival WX09 NBCycle can be found here and here.

Cycle for Survival has raised more than $140 million since it was founded in 2007, with $110 million raised in the past four years. More than 34,000 participants and 230,000 donors are expected to support Cycle for Survival's indoor team cycling events in 2018. Instructors from Equinox, Cycle for Survival's founding partner, will lead the annual rides in January, February and March in 16 cities across the country. For more information about Cycle for Survival, please visit


About Cycle for Survival
Join the Battle. Cycle for Survival is the movement to beat rare cancers. Since 2007, Cycle for Survival has raised $140 million through its signature indoor team cycling events across the United States to help fund pioneering rare cancer research led by Memorial Sloan Kettering Cancer Center, which owns and operates Cycle for Survival. 100 percent of every donation funds rare cancer research. About half of all cancer patients are fighting a rare cancer, and they often face limited or no treatment options. Together with the movement's founding partner, Equinox, Cycle for Survival has supported innovative clinical trials, research studies and major scientific initiatives. For a list of events, research updates and additional information, visit and follow Cycle for Survival on FacebookTwitterInstagram, and YouTube

About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSK)—the world's oldest and largest private cancer center—has devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs. Today, it is one of 69 National Cancer Institute-designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment. The close collaboration between MSK's physicians and scientists is one of its unique strengths, enabling it to provide patients with the best care available as researchers work to discover more effective strategies to prevent, control and ultimately cure cancer. MSK's education programs train future physicians and scientists, and the knowledge and experience they gain has an impact on cancer treatment and biomedical research around the world.

About New Balance
New Balance, headquartered in Boston, MA has the following mission: Demonstrating responsible leadership, we build global brands that athletes are proud to wear, associates are proud to create and communities are proud to host. Manufactured in the U.S. for over 75 years and representing a limited portion of our U.S. sales, New Balance Made U.S. is a premium collection that contains a domestic value of 70% or greater. New Balance owns five factories in New England and one in Flimby, U.K. New Balance employs more than 6,000 associates around the globe, and in 2016 reported worldwide sales of $3.8 billion. To learn more about New Balance, please visit and for the latest press information please visit

View original content with multimedia:

SOURCE Cycle for Survival

PR Newswire

Last updated on: 01/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.